China a priority for Novartis’ Narasimhan

Novartis CEO Vasant Narasimhan says capitalizing on the rise of China, by prioritizing drug launches in the country, will be a key pillar of the pharma’s strategy over the next few years.

A second pillar will be M&A that builds depth in Novartis’ core therapeutic areas. ...